• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Zyduslife Share Price

    Zydus Lifesciences Share PriceZydus Lifesciences

    Large Cap 10k Result
    ₹657.95
    22.5 (3.54%)
    • Advice
    • Hold
    As on 07 December, 2023 | 18:29 BSE: 532321 NSE: ZYDUSLIFEISIN: INE010B01027

    Zydus Lifesciences Performance

    Day Range

    • Low 634.90
    • High 659.60
    ₹ 657.95

    52 Week Range

    • Low 403.20
    • High 668.75
    ₹ 657.95
    • Open Price639.20
    • Previous Close635.45
    • Volume2533954

    Start SIP in Zydus Lifesciences

    Start SIP

    Zydus Lifesciences Share Price

    • Over 1 Month 10.15%
    • Over 3 Month 3.94%
    • Over 6 Month 27.73%
    • Over 1 Year 62.36%

    Zydus Lifesciences Key Statistics

    P/E Ratio 23.7
    PEG Ratio 0.5
    Market Cap Cr 66,598
    Price to Book Ratio 3.4
    EPS 16
    Dividend 0.9
    Relative Strength Index 69.17
    Money Flow Index 78.03
    MACD Signal 9.66
    Average True Range 12.93

    Zydus Lifesciences F&O

    Zydus Lifesciences Futures
    Zydus Lifesciences Option Chain

    Zydus Lifesciences Investment Rating

    • Master Rating:

    • Zydus Lifesciences has an operating revenue of Rs. 18,881.30 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 15% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 87 which is a GOOD score indicating consistency in earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Zydus Lifesciences Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2,1592,9562,4372,0872,2171,9811,919
    Operating Expenses Qtr Cr 1,5101,8151,8071,6281,7201,4371,562
    Operating Profit Qtr Cr 6491,141773459679544458
    Depreciation Qtr Cr 125121120122124123123
    Interest Qtr Cr 91908589644142
    Tax Qtr Cr 163232124129149101100
    Net Profit Qtr Cr 805781491256451332247
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 9,2808,161
    Operating Expenses Annual Cr 6,2776,064
    Operating Profit Annual in Cr 2,4541,918
    Depreciation Cr 489479
    Interest Annual Cr 278135
    Tax Annual Cr 503306
    Net Profit Annual Cr 1,529858
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 1,0781,311
    Cash from Investing Activity Annual Cr -1,960768
    Cash from Financing Annual Activity Cr 827-1,710
    Net Cash Flow Annual Cr -55369
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 13,63913,241
    Fixed Assets Annual Cr 4,9234,720
    Total Non Current Assets Annual Cr 13,40510,903
    Total Current Assets Annual Cr 7,1586,837
    Total Assets Annual Cr 20,56417,740
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 135129
    ROE Annual % 116
    ROCE Annual % 1412
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3426
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 4,3695,1404,8534,3623,9434,0733,742
    Operating Expenses Qtr Cr 3,2233,6343,7553,4063,3193,2403,146
    Operating Profit Qtr Cr 1,1461,5051,256956815833718
    Depreciation Qtr Cr 184180179182182181185
    Interest Qtr Cr 9182833353439
    Tax Qtr Cr 226216137195137118109
    Net Profit Qtr Cr 8011,087297623523518397
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 17,42415,490
    Operating Expenses Annual Cr 13,37811,925
    Operating Profit Annual in Cr 3,8603,341
    Depreciation Cr 723713
    Interest Annual Cr 130127
    Tax Annual Cr 588512
    Net Profit Annual Cr 1,9604,487
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 2,6892,104
    Cash from Investing Activity Annual Cr 1,1711,154
    Cash from Financing Annual Activity Cr -4,400-868
    Net Cash Flow Annual Cr -5402,390
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 17,51617,000
    Fixed Assets Annual Cr 7,9177,550
    Total Non Current Assets Annual Cr 15,74015,534
    Total Current Assets Annual Cr 10,01612,261
    Total Assets Annual Cr 25,75627,795
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 195186
    ROE Annual % 1126
    ROCE Annual % 1614
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2323
    Invest in Zydus Lifesciences

    Zydus Lifesciences Technicals

    EMA & SMA

    Current Price
    ₹657.95
    22.5 (3.54%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹630.35
    • 50 Day
    • ₹618.42
    • 100 Day
    • ₹604.44
    • 200 Day
    • ₹568.43
    • 20 Day
    • ₹632.85
    • 50 Day
    • ₹608.26
    • 100 Day
    • ₹620.31
    • 200 Day
    • ₹566.16

    Zydus Lifesciences Resistance and Support

    PIVOT
    ₹650.82
    Resistance
    First Resistance 666.73
    Second Resistance 675.52
    Third Resistance 691.43
    RSI 69.17
    MFI 78.03
    MACD Single Line 9.66
    MACD 10.19
    Support
    First Resistance 642.03
    Second Resistance 626.12
    Third Resistance 617.33

    Zydus Lifesciences Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 1,516,735 81,054,318 53.44
    Week 1,157,658 66,264,321 57.24
    1 Month 1,170,034 52,873,845 45.19
    6 Month 1,167,258 56,460,290 48.37

    Zydus Lifesciences Result Highlights

    Zydus Lifesciences Synopsis

    NSE-Medical-Generic Drugs

    Zydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 8731.60 Cr. and Equity Capital is Rs. 101.20 Cr. for the Year ended 31/03/2023. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.
    Market Cap 65,059
    Sales 9,781
    Shares in Float 25.31
    No of funds 341
    Yield 0.95
    Book Value 4.71
    U/D Vol ratio 1
    LTDebt / Equity 28
    Alpha 0.16
    Beta 0.49

    Zydus Lifesciences

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 74.98%74.98%74.98%74.98%
    Mutual Funds 5.94%5.8%5.59%5.56%
    Insurance Companies 6.86%7.43%7.67%7.87%
    Foreign Portfolio Investors 4.85%4.04%3.42%2.52%
    Financial Institutions/ Banks
    Individual Investors 5.66%5.97%6.42%7.04%
    Others 1.71%1.78%1.92%2.03%

    Zydus Lifesciences Management

    Name Designation
    Mr. Pankaj R Patel Chairman
    Dr. Sharvil P Patel Managing Director
    Mr. Ganesh N Nayak Executive Director
    Mr. Bhadresh K Shah Independent Director
    Mr. Mukesh M Patel Non Executive Director
    Mr. Nitin R Desai Independent Director
    Ms. Dharmishtaben N Raval Independent Woman Director
    Ms. Apurva S Diwanji Independent Director
    Mrs. Upasana Konidela Independent Woman Director
    Mr. Monappa Arun Akhil Independent Director

    Zydus Lifesciences Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Zydus Lifesciences Corporate Action

    Date Purpose Remarks
    2023-11-07 Quarterly Results
    2023-08-11 Quarterly Results
    2023-05-18 Audited Results & Final Dividend
    2023-02-03 Quarterly Results
    2022-11-11 Quarterly Results
    Date Purpose Remarks
    2023-07-28 FINAL Rs.6.00 per share(600%)Final Dividend
    2022-07-29 FINAL Rs.2.50 per share(250%)Final Dividend

    Zydus Lifesciences MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 63,981
    Parag Parikh Flexi Cap Regular Growth 44,038
    ICICI Prudential Bluechip Fund Growth 41,269
    Kotak Flexicap Fund Growth 39,269
    Kotak Emerging Equity Scheme Growth 33,700

    About Zydus Lifesciences

    Zydus Lifesciences Limited (Zydus) is one of India’s leading pharmaceutical companies, engaged in the formulation and marketing of pharmaceutical products. Zydus Group has a leadership position in several segments in its portfolio with brands that are market leaders in their respective categories. 

    The Group has a strong presence across therapeutic segments including pain management, cardiovascular diseases, urology and anti-infectives. It also offers over-the-counter healthcare products. It sells medicines through retail pharmacies, hospitals, and clinics to customers all over India and exports to various countries worldwide. 

    The Company is organized into three business verticals: Pharmaceuticals, Active Ingredients and Contract Manufacturing Services (CMS). It manufactures active ingredients for use in formulations manufactured by other pharmaceutical companies; distributes finished formulations; provides contract manufacturing services for branded drugs, and markets finished formulations under its brand names.

    Business Verticals

    Zydus Lifesciences has three business divisions. The largest division is pharmaceuticals, which includes oral solid dosage and injectables. The second division is hospital equipment and supplies. Finally, there is a medical education division that includes training programs for medical professionals in both rural and urban areas as well as retail stores selling over-the-counter products to consumers.  

    In addition to these divisions, Zydus Lifesciences provides consulting services for companies looking to enter or expand their presence in India. These services include regulatory and market access assistance, drug registration services, strategic marketing support and distribution channel optimization.

     

    Milestones

    1995 - Cadila Healthcare Ltd, the flagship company of the Zydus Cadila Group, was founded.

    1996 - It went public in July. They also formed a strategic alliance with Gulin Pharma of China and launched Falcigo, an anti-malarial segment, in India.

    2000 - In May, the company acquired Recon Ltd's formulation business, to strengthen its position in the southern market.

    2001 - Acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector at the time. The same year they formed a joint venture with US-based Onconova for collaborative research in the field of Oncogenomics.

    2002 - In April, the company acquired Banyan Chemicals, a Vadodara-based company registered with the US Food and Drug Administration.

    2003 - Zydus Group decided to merge German Remedies Ltd and Recon Healthcare Ltd with Cadila Healthcare Ltd

    2004 - In November, the company formed a strategic alliance with the Zambon Group in Italy to explore new opportunities in contract manufacturing. The same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to manufacture and market BI's products in India.

    2005 - The company formed a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a Tyco Healthcare business unit, to market the company's product under a joint label. In the same year, the company formed a 50:50 joint venture with Australia's Mayne Pharma to produce generic injectable cytotoxic (anti-cancer) medicines as well as active pharmaceutical ingredients (API) for global markets.

    2005-06 - During this fiscal year, the company formed a 50:50 joint venture with one of India's leading biotech companies, Bharat Serums and Vaccines Ltd (BSV), to develop, manufacture, and market a non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anticancer product for global markets.

    2006-07 - During this fiscal year, the company entered into a share purchase agreement to acquire a 97.95 per cent stake in Liva Healthcare Ltd, which manufactures and markets Formulations. They also built a brand-new green field facility for Solid Oral Dosage. They also built a Lyophilisation facility at the Moraiya plant with an annual capacity of 7.5 million dosages to serve both the Indian and international markets.

    2007-08 - During this fiscal year, the company restructured its formulation division, Alidac, and launched two new subdivisions, Corza and Fortiza.
     

    Zydus Lifesciences FAQs

    What is Share Price of Zydus Lifesciences ?

    Zydus Lifesciences share price is ₹657 As on 07 December, 2023 | 18:15

    What is the Market Cap of Zydus Lifesciences ?

    The Market Cap of Zydus Lifesciences is ₹66598 Cr As on 07 December, 2023 | 18:15

    What is the P/E ratio of Zydus Lifesciences ?

    The P/E ratio of Zydus Lifesciences is 23.7 As on 07 December, 2023 | 18:15

    What is the PB ratio of Zydus Lifesciences ?

    The PB ratio of Zydus Lifesciences is 3.4 As on 07 December, 2023 | 18:15

    What were the company's most recent reported sales and net income?

    Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20  crores in FY22

    What is the future of the company's shares?

    Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.

    How to buy shares of Zydus Lifesciences Ltd.?

    The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.